Takeaways: Tevimbra’s completed pCPA negotiations strengthen BeOne’s position in Canada’s NPC immunotherapy market and could establish an early publicly funded first-line option. Prov...
Takeaways: Completing pCPA negotiations is a key step toward public reimbursement for Nemluvio in Canada, which—once provincial/territorial drug plans list it—should materially expand access for...
Takeaways: The pCPA Letter of Intent for Anzupgo (delgocitinib cream) moves Canada closer to public reimbursement for the first topical therapy specifically indicated for moderate to severe chro...
Takeaways: Siliq’s listing under Alberta’s public drug plan expands brodalumab’s public coverage across Canada, leaving only British Columbia without provincial reimbursement and improving...
Takeaways: CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not ...
Takeaways: The positive reimbursement recommendation from Canada’s drug agency moves Leqembi closer to public funding for early Alzheimer’s disease, which can significantly expand the ...
Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways: The decision strengthens Pfizer’s foothold in Canada’s publicly funded pediatric pneumococcal market by making Prevnar 20 the standard for infants in two large provinces, wh...
Takeaways: Alberta’s coverage broadens Elidel’s public-access footprint in Canada and should make it easier for dermatologists to use a non-corticosteroid topical when conventional therapies are...
